These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Antiviral activity and mode of action of a peptide isolated from Sorghum bicolor. Camargo Filho I; Cortez DA; Ueda-Nakamura T; Nakamura CV; Dias Filho BP Phytomedicine; 2008 Mar; 15(3):202-8. PubMed ID: 17890069 [TBL] [Abstract][Full Text] [Related]
8. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Nijhuis M; van Maarseveen NM; Boucher CA Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205 [TBL] [Abstract][Full Text] [Related]
9. Effects of lyophilization on the infectivity of enveloped and non-enveloped viruses in bone tissue. Uhlenhaut C; Dörner T; Pauli G; Pruss A Biomaterials; 2005 Nov; 26(33):6558-64. PubMed ID: 15946737 [TBL] [Abstract][Full Text] [Related]
10. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Guzman EM; Cheshenko N; Shende V; Keller MJ; Goyette N; Juteau JM; Boivin G; Vaillant A; Herold BC Antivir Ther; 2007; 12(8):1147-56. PubMed ID: 18240855 [TBL] [Abstract][Full Text] [Related]
11. 2-deoxy-D-glucose as a potential drug against fusogenic viruses including HIV. Parris GE Med Hypotheses; 2008; 70(4):776-82. PubMed ID: 17920779 [TBL] [Abstract][Full Text] [Related]
12. Genetic diversity-independent neutralization of pandemic viruses (e.g. HIV), potentially pandemic (e.g. H5N1 strain of influenza) and carcinogenic (e.g. HBV and HCV) viruses and possible agents of bioterrorism (variola) by enveloped virus neutralizing compounds (EVNCs). Kotwal GJ Vaccine; 2008 Jun; 26(24):3055-8. PubMed ID: 18241960 [TBL] [Abstract][Full Text] [Related]
13. Spray-dried lipid-hyaluronan-polymethacrylate microparticles for drug delivery in the peritoneum. Domnina YA; Yeo Y; Tse JY; Bellas E; Kohane DS J Biomed Mater Res A; 2008 Dec; 87(3):825-31. PubMed ID: 18257078 [TBL] [Abstract][Full Text] [Related]
14. Viral infectivity is maintained by an RNA protection buffer. Uhlenhaut C; Kracht M J Virol Methods; 2005 Sep; 128(1-2):189-91. PubMed ID: 15936833 [TBL] [Abstract][Full Text] [Related]
16. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma. Kim IS; Choi YW; Kang Y; Sung HM; Shin JS J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304 [TBL] [Abstract][Full Text] [Related]
17. Engineered nanoparticles of Efavirenz using methacrylate co-polymer (Eudragit-E100) and its biological effects in-vivo. Hari BNV; Narayanan N; Dhevendaran K; Ramyadevi D Mater Sci Eng C Mater Biol Appl; 2016 Oct; 67():522-532. PubMed ID: 27287151 [TBL] [Abstract][Full Text] [Related]
18. Co-operative thermal inactivation of herpes simplex virus and influenza virus by arginine and NaCl. Utsunomiya H; Ichinose M; Tsujimoto K; Katsuyama Y; Yamasaki H; Koyama AH; Ejima D; Arakawa T Int J Pharm; 2009 Jan; 366(1-2):99-102. PubMed ID: 18845231 [TBL] [Abstract][Full Text] [Related]
19. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization. Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665 [TBL] [Abstract][Full Text] [Related]
20. Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Hwu JR; Singha R; Hong SC; Chang YH; Das AR; Vliegen I; De Clercq E; Neyts J Antiviral Res; 2008 Feb; 77(2):157-62. PubMed ID: 17977606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]